NeuroRPM to provide AI monitoring for Annovis Parkinson’s trial
NeuroRPM’s FDA-cleared wearable platform will play a key role in Annovis Bio’s ANVS-25002 open-label trial for Parkinson’s disease, which aims to enroll around 500 participants. This innovative study allows participants to opt into NeuroRPM monitoring, enhancing traditional assessments with continuous tracking of real-world symptoms. Utilizing the Apple Watch, the platform passively collects movement data to measure motor symptoms such as bradykinesia, tremor, and dyskinesia.
This development is significant for the longevity and healthspan field as it represents a shift towards real-time, data-driven insights in clinical trials. The integration of advanced algorithms and AI-enabled monitoring provides researchers with a more nuanced understanding of treatment responses, potentially leading to improved therapeutic strategies for Parkinson’s disease.
A key takeaway is that the use of continuous digital biomarkers could redefine how clinical trials are conducted, paving the way for more personalized and effective interventions in neurodegenerative diseases.